MX2021008318A - Nuevos polipeptidos de union especifica y usos de los mismos. - Google Patents

Nuevos polipeptidos de union especifica y usos de los mismos.

Info

Publication number
MX2021008318A
MX2021008318A MX2021008318A MX2021008318A MX2021008318A MX 2021008318 A MX2021008318 A MX 2021008318A MX 2021008318 A MX2021008318 A MX 2021008318A MX 2021008318 A MX2021008318 A MX 2021008318A MX 2021008318 A MX2021008318 A MX 2021008318A
Authority
MX
Mexico
Prior art keywords
polypeptides
novel
specific
diagnostic
swiss prot
Prior art date
Application number
MX2021008318A
Other languages
English (en)
Inventor
Andrea Allersdorfer
Marlon Hinner
Alexander Wiedenmann
Original Assignee
Pieris Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pieris Pharmaceuticals Gmbh filed Critical Pieris Pharmaceuticals Gmbh
Publication of MX2021008318A publication Critical patent/MX2021008318A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)

Abstract

La presente invención se relaciona con novedosos polipéptidos terapéuticos y/o diagnósticos, de unión específica, dirigidos contra la diana de Swiss Prot Q16552 y novedosos polipéptidos terapéuticos y/o diagnósticos, de unión específica, dirigidos contra la diana Swiss Prot Q9NPF7. Además, la presente invención se relaciona con novedosos polipéptidos terapéuticos y/o diagnósticos, de unión específica, dirigidos contra una o ambas de Swiss Prot Q16552 y Swiss Prot Q9NPF7. La invención también se relaciona con moléculas de ácido nucleico que codifican para dichos polipéptidos y a métodos para generar dichos polipéptidos y moléculas de ácido nucleico. Además, la invención está dirigida a composiciones que comprenden los polipéptidos, y usos terapéuticos y/o diagnósticos de estos polipéptidos.
MX2021008318A 2014-05-22 2016-11-18 Nuevos polipeptidos de union especifica y usos de los mismos. MX2021008318A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14169488 2014-05-22

Publications (1)

Publication Number Publication Date
MX2021008318A true MX2021008318A (es) 2021-08-05

Family

ID=50771150

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016015235A MX2016015235A (es) 2014-05-22 2015-05-20 Nuevos polipeptidos de union especifica y usos de los mismos.
MX2021008318A MX2021008318A (es) 2014-05-22 2016-11-18 Nuevos polipeptidos de union especifica y usos de los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016015235A MX2016015235A (es) 2014-05-22 2015-05-20 Nuevos polipeptidos de union especifica y usos de los mismos.

Country Status (14)

Country Link
US (2) US10774119B2 (es)
EP (2) EP3789397B1 (es)
JP (2) JP6753784B2 (es)
KR (1) KR20170004011A (es)
CN (2) CN113621050A (es)
AU (2) AU2015261968B2 (es)
BR (1) BR112016027024A2 (es)
CA (2) CA3170782A1 (es)
DK (1) DK3145945T3 (es)
ES (1) ES2823563T3 (es)
MX (2) MX2016015235A (es)
RU (1) RU2723034C2 (es)
SG (2) SG11201609274SA (es)
WO (1) WO2015177175A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10526384B2 (en) 2012-11-19 2020-01-07 Pieris Pharmaceuticals Gmbh Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof
CN113621050A (zh) 2014-05-22 2021-11-09 皮里斯制药有限公司 新型特异性结合多肽及其用途
EP3383921A4 (en) * 2015-11-30 2019-04-17 Pieris Australia Pty Ltd. NOVEL ANTI-ANGIOGENIC FUSION POLYPEPTIDES
JP2020530453A (ja) 2017-08-09 2020-10-22 マサチューセッツ インスティテュート オブ テクノロジー アルブミン結合ペプチド結合体及びその方法
KR20210016434A (ko) * 2018-05-31 2021-02-15 홍콩 폴리테크닉 유니버시티 아르기닌-고갈제의 조성 및 이의 암, 비만, 대사 장애 및 관련 합병증 및 동반질환에의 적용
EP3599245A1 (en) * 2018-07-27 2020-01-29 Dompé farmaceutici S.p.A. Il-17a binding polypeptides and medical uses thereof
CN109096373B (zh) * 2018-09-27 2022-06-21 江苏亨瑞生物医药科技有限公司 合成寡肽及其用途
CN109206485B (zh) * 2018-09-27 2022-04-08 山东聚胜生物科技有限公司 一种防治肺癌转移的寡肽
CN109180789B (zh) * 2018-09-27 2022-08-19 上海揽微赛尔生物科技有限公司 一种寡肽及制药应用
CN109096374B (zh) * 2018-09-27 2022-11-18 深圳乐土沃森精准医疗有限公司 一种抑制肺癌转移的合成寡肽
EP3946417A1 (en) 2019-03-29 2022-02-09 Pieris Pharmaceuticals GmbH Inhaled administration of lipocalin muteins
MX2022013923A (es) * 2020-05-05 2023-02-09 Janssen Biotech Inc Metodos para tratar la enfermedad de crohn con el anticuerpo especifico anti-il23.
CN114805546B (zh) * 2022-06-08 2024-05-28 宁波市健康口腔医学研究院 一种检测口腔癌的t细胞表位多肽及其应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3779221D1 (de) 1986-08-19 1992-06-25 Genentech Inc Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und -zytokinen.
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
WO1995031479A1 (en) 1994-05-18 1995-11-23 Inhale Therapeutic Systems, Inc. Methods and compositions for the dry powder formulation of interferons
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
WO1996023879A1 (en) 1995-01-30 1996-08-08 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
WO1998016873A1 (fr) 1996-10-14 1998-04-23 Firm Forsat Ltd. Procede de preparation de dispersions a base de composants chromogenes
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
CA2334267C (en) 1998-06-08 2009-02-17 F. Hoffmann-La Roche Ag Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
EP1377306A1 (en) 2001-03-09 2004-01-07 Dyax Corp. Serum albumin binding moieties
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
WO2003029471A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
EP1658308A1 (en) 2003-08-25 2006-05-24 Pieris ProteoLab AG Muteins of a bilin-binding protein with affinity for a given target
JP2007284351A (ja) 2004-07-27 2007-11-01 Osaka Bioscience Institute アミロイド蛋白質の凝集を抑制する物質とその作用
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
JP2009509535A (ja) 2005-09-27 2009-03-12 アムニクス， インコーポレイテッド タンパク様薬剤およびその使用
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
SG173332A1 (en) * 2006-08-01 2011-08-29 Pieris Ag Muteins of tear lipocalin and methods for obtaining the same
CN101516907B (zh) * 2006-08-01 2015-08-26 皮里斯股份公司 泪液脂质运载蛋白的突变蛋白及其获得方法
ATE554791T1 (de) 2007-02-23 2012-05-15 Schering Corp Gentechnisch hergestellte anti-il-23p19- antikörper
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
CA2702611A1 (en) 2007-10-19 2009-04-23 Abbott Laboratories Immunoassays and kits for the detection of ngal
AU2009209591B2 (en) * 2008-01-30 2012-08-02 Pieris Ag Muteins of tear lipocalin having affinity to human c-Met receptor tyrosine kinase and methods for obtaining the same
WO2009156456A1 (en) 2008-06-24 2009-12-30 Technische Universität München Muteins of hngal and related proteins with affinity for a given target
EP2330897A4 (en) * 2008-09-18 2013-11-27 Univ Columbia NGAL-BINDING SIDEROPHORES AND THEIR USE FOR THE TREATMENT OF IRON DEFICIENCY AND IRON SURPLUS
WO2011069992A2 (en) 2009-12-07 2011-06-16 Pieris Ag Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
PT2580236T (pt) 2010-06-08 2019-05-30 Astrazeneca Ab Muteínas da lipocalina de lágrima, que se ligam ao recetor-alfa da il-4
RU2577964C2 (ru) 2010-07-09 2016-03-20 Аффибоди Аб Полипептиды
NZ606584A (en) 2010-08-16 2014-10-31 Pieris Ag Binding proteins for hepcidin
DK2640740T3 (en) 2010-11-15 2017-06-26 Pieris Pharmaceuticals Gmbh MUTEINS OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR GLYPICAN-3 (GPC3)
UA117218C2 (uk) * 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
EP3453400B1 (en) 2011-12-13 2021-01-20 Pieris Pharmaceuticals GmbH Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
US10526384B2 (en) 2012-11-19 2020-01-07 Pieris Pharmaceuticals Gmbh Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof
WO2015104406A2 (en) * 2014-01-13 2015-07-16 Pieris Ag Multi-specific polypeptide useful for localized tumor immunomodulation
CN113621050A (zh) 2014-05-22 2021-11-09 皮里斯制药有限公司 新型特异性结合多肽及其用途
MX2017009767A (es) 2015-01-28 2018-08-15 Pieris Pharmaceuticals Gmbh Nuevas proteínas específicas para la angiogénesis.
MX2017010628A (es) 2015-02-18 2017-12-07 Sanofi Sa Proteinas especificas novedosas para pioverdina y pioquelina.
CA2980839A1 (en) 2015-05-04 2016-11-10 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
CN114456252A (zh) 2015-05-18 2022-05-10 皮里斯制药有限公司 对磷脂酰肌醇聚糖-3（gpc3）具有亲和力的人脂质运载蛋白2的突变蛋白
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白

Also Published As

Publication number Publication date
EP3789397B1 (en) 2023-12-06
CA2949405C (en) 2023-08-01
JP2017518748A (ja) 2017-07-13
US10774119B2 (en) 2020-09-15
EP3145945B1 (en) 2020-07-15
US11345728B2 (en) 2022-05-31
WO2015177175A3 (en) 2016-02-18
US20170107266A1 (en) 2017-04-20
AU2015261968A1 (en) 2016-11-24
US20200377563A1 (en) 2020-12-03
RU2016149596A3 (es) 2019-01-22
CA3170782A1 (en) 2015-11-26
SG11201609274SA (en) 2016-12-29
CN106573964A (zh) 2017-04-19
RU2016149596A (ru) 2018-06-26
JP6753784B2 (ja) 2020-09-09
JP7084965B2 (ja) 2022-06-15
KR20170004011A (ko) 2017-01-10
MX2016015235A (es) 2017-06-29
CN106573964B (zh) 2021-07-16
RU2723034C2 (ru) 2020-06-08
AU2015261968B2 (en) 2018-11-22
AU2019201007A1 (en) 2019-03-07
SG10201912019WA (en) 2020-02-27
DK3145945T3 (da) 2020-09-28
AU2019201007B2 (en) 2020-10-22
JP2021035358A (ja) 2021-03-04
WO2015177175A2 (en) 2015-11-26
CN113621050A (zh) 2021-11-09
EP3145945A2 (en) 2017-03-29
CA2949405A1 (en) 2015-11-26
EP3789397A1 (en) 2021-03-10
ES2823563T3 (es) 2021-05-07
BR112016027024A2 (pt) 2017-10-31

Similar Documents

Publication Publication Date Title
MX2021008318A (es) Nuevos polipeptidos de union especifica y usos de los mismos.
WO2014076321A8 (en) Novel specific-binding polypeptides and uses thereof
MX2023008686A (es) Polinucleotidos moduladores.
MX2017004838A (es) Composiciones de interleucina-15 y usos de estas.
TW201613880A (en) Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
MX2016002571A (es) Regulador de ph de transduccion.
MX2017001279A (es) Usos y composiciones de la flagelina.
PH12016501441A1 (en) Chimeric alkaline phosphate-like proteins
PH12017501077A1 (en) Compositions and methods for antibodies targeting bmp6
MX2017009767A (es) Nuevas proteínas específicas para la angiogénesis.
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
CR20200290A (es) PÉPTIDOS Y COMPOSICIONES PARA EL TRATAMIENTO DE DAÑO ARTICULAR (Divisional 2015-0466)
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
PH12016501444A1 (en) Antibodies against f glycoprotein of hendra and nipah viruses
TR201901146T4 (tr) İndigo naturalisten bir ekstrakt ve bunun hazırlanmasına yönelik bir proses.
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2019005855A (es) Formulaciones que se pueden pulverizar.
MX2017002388A (es) Composiciones para fibras de queratina.
PH12018501114A1 (en) Polypeptides inhibiting cd40l
PH12016500495A1 (en) Compositions for the treatment of hypertension and/or fibrosis
EA201890209A1 (ru) Композиция, содержащая танины
MY182818A (en) Compositions for the treatment of fibrosis and fibrosis-related conditions
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
PH12017501147A1 (en) Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs